Across TCGA pan-cancer cohorts, MTND4P23 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated MTND4P23 data layer.
The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher MTND4P23 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTND4P23 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.
DLBC, COAD, and ESCA are the cancer types where MTND4P23 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.